Neoadjuvant Immunotherapy Shows High Response Rates in Desmoplastic Melanoma
Feb 27, 2026
Neoadjuvant pembrolizumab achieved 71% pathologic complete response in desmoplastic melanoma patients, while lower-dose ipilimumab combination therapy showed improved survival and fewer side effects in advanced melanoma treatment.